Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT05204940 Recruiting - Depression Clinical Trials

Longitudinal Observational Biomarker Study

OPT-Neuro
Start date: September 27, 2017
Phase:
Study type: Observational

The purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.

NCT ID: NCT05202197 Completed - Alzheimer Disease Clinical Trials

Smart Cupboard-based System for Memory Assessment in Alzheimer's Patients

Start date: October 30, 2021
Phase:
Study type: Observational

The main objective of the research is to create a tool that can make a good diagnosis of cognitive abilities in Alzheimer's patients. As a secondary objective, we intend to examine both the percentage of correct answers and the response times and see their relationship with age, gender, sex, months since the onset of the disease and years of training.

NCT ID: NCT05201534 Not yet recruiting - Child Development Clinical Trials

Interventions in Mathematics and Cognitive Skills

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate neurocognitive mechanisms underlying response to intervention aimed at enhancing, and remediating weaknesses in, numerical skills in children, including those with mathematical learning disabilities (MLD).

NCT ID: NCT05200962 Not yet recruiting - Schizophrenia Clinical Trials

Electrical Brain Stimulation for Cognitive Impairment in Schizophrenia: a tDCS-fMRI Study

Start date: February 1, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the mechanism of action of transcranial electrical brain stimulation over the dorsolateral prefrontal cortex for cognitive impairment in schizophrenia. To do so the effect of a novel stimulation protocol will be investigated in the fMRI scanner.

NCT ID: NCT05200897 Recruiting - Alzheimer Disease Clinical Trials

Transdermal Trigeminal Electrical Neuromodulation on Mild Cognitive Impairment With Insomnia

Start date: November 3, 2021
Phase: N/A
Study type: Interventional

This study aims to validate the safety and impact of transdermal trigeminal electrical neuromodulation(Cefaly) on mild cognitive impairment patients with insomnia on brain functional and structural connectivity as well as sleep parameters evidenced by polysomnography and sleep surveys, with consideration for amyloid positivity and brain-derived neurotrophic factor .

NCT ID: NCT05200572 Not yet recruiting - Clinical trials for Cognitive Impairment, Mild

Study of a Behavioral Intervention for Older Advanced Cancer Patients and Their Caregivers

Start date: January 15, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to test the feasibility of a telehealth Dyadic Life Review (DLR), adapted from individual Life Review Therapy, with caregivers of older adults with advanced cancer, including those with Mild Cognitive Impairment (MCI). The study will enroll 20 dyads of caregivers and older patients with advanced cancer and 20 dyads of caregivers and patients with advanced cancer and Mild Cognitive Impairment (MCI).

NCT ID: NCT05199142 Recruiting - Cognitive Decline Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline

Start date: September 23, 2021
Phase: Phase 1
Study type: Interventional

This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on elderly male and female study participants with cognitive decline at screening.

NCT ID: NCT05198726 Not yet recruiting - Clinical trials for Mild Cognitive Impairment

Speed of Processing (SoP) Training Plus α-tACS

aMCIUp
Start date: February 2022
Phase: N/A
Study type: Interventional

The current proposal aims to assess if Speed of Processing (SoP) Training combined with alpha tACS (α-tACS) is able to increase brain speed of processing as assessed by the Useful Field of View (UFOV) when comparing to SoP training and sham α-tACS. Moreover, a second aim is to assess if those changes in speed of processing transfer to other cognitive domains, such as memory, language and executive functioning. Furthermore, the mechanisms underlying these interventions will be tested, namely to assess brain connectivity and coherence as assessed by EEG. To that purpose, the aim of the current proposal is to conduct a double-blind, parallel randomized trial assessing the effects of combining SoP with alpha endogenous tACS (either active or sham) in people with Mild Cognitive impairment (MCI).

NCT ID: NCT05195398 Not yet recruiting - Stroke Clinical Trials

TDCS to Improve Post-Stroke Cognitive Impairment

TIPSCI
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The investigators will conduct a randomized, double-blinded, sham-controlled trial of approximately 60 patients with minor stroke and post-stroke mild cognitive impairment (psMCI). Participants will be individually randomized on enrollment using a random number generator to treatment with anodal tDCS + computerized cognitive treatment (CCT) versus sham + CCT (approximately 30 patients in each arm). Clinical evaluation including assessment of cognition will be performed pre- and post-intervention by individuals on the study team blinded to the participant's intervention. Participants will also undergo functional neuroimaging with magnetoencephalography (MEG) pre- and post-intervention (1, 3, and 6 months post-stroke to evaluate for initial and longer-term effects of treatment on cerebral activation patterns and functional connectivity). Neuroimaging and clinical outcomes will be assessed to determine the effect of tDCS versus sham + CCT on psMCI.

NCT ID: NCT05194787 Recruiting - Alzheimer Disease Clinical Trials

TAS Test: Online Motor-cognitive Tests for Early Detection of Alzheimer's Disease

TASTest
Start date: March 5, 2021
Phase:
Study type: Observational

Global dementia prevalence is rising. Alzheimer's disease (AD), the most common cause, has devastating effects on people's quality of life. AD has a preclinical (pre-AD) period of 10-20 years when brain pathology silently progresses before any cognitive symptoms appear. Current tests for pre-AD are invasive, costly and unsuitable for screening at population level. Similar to screening for pre-diabetes and carcinoma in situ, it is important to detect AD at the preclinical stage in order to offer early interventions before the pathology progresses to the irrerversible degenerative stage. In the study, research will develop a new scalable test (TAS Test) by combining two innovative ideas: hand-movement tests to detect pre-AD >10 years before cognitive symptoms begin; and computer vision so people can "self-test" online using home computers. This unique approach builds on recent discoveries that hand-movement patterns change in pre-AD. The research team will use exquisitely precise computer vision methods to automatically analyse movement data from thousands of participants, and combine this with machine learning of overall motor-cognitive performance. The project team has access to 3 well-phenotyped cohorts, >10,000 existing participants and a cutting-edge assay for a blood AD biomarker, ptau181. The research team will develop a TAS Test algorithm to classify hand-movement and cognitive test data for pre-AD risk (p-taua181 levels) and determine TAS Test's precision to prospectively predict 5-year risks of cognitive decline and AD.